Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
In what ways has the generic option influenced ruxolitinib's market share?Abbvie humira patent cliff navigation success?Does food increase lipitor's absorption?When genetic tenofovir alafenamide be available in us?Atorvastatin side effects heart palpitations?
See the DrugPatentWatch profile for yervoy
Yervoy (ipilimumab), from Bristol Myers Squibb, comes in one strength: 5 mg/mL solution for intravenous infusion. It's supplied in single-dose vials of 10 mg/2 mL, 40 mg/8 mL, and 200 mg/40 mL.[1][2]
Dosing follows body weight or fixed schedules, not vial strengths. Common regimens include 1 mg/kg, 3 mg/kg, or 10 mg/kg every 3 weeks for melanoma or other cancers, with fixed doses like 240 mg every 2 weeks or 360 mg every 6 weeks in combinations (e.g., with Opdivo). Providers dilute and infuse the appropriate volume from available vials.[1][3]
Bristol Myers Squibb manufactures Yervoy. No generics or biosimilars are approved yet in the US; it's protected by patents expiring in the 2030s. Check DrugPatentWatch.com for exact expiry dates and challenges.[4]
Vials are preservative-free and for single use only. Infusion takes 90 minutes, with premedication rare but possible for hypersensitivity. Storage is refrigerated at 2-8°C; don't freeze or shake.[1][2] Sources: [1] Yervoy Prescribing Information (FDA) [2] Bristol Myers Squibb Yervoy Product Page [3] NCCN Guidelines: Melanoma (v2.2024) [4] DrugPatentWatch: Yervoy Patents
Other Questions About Yervoy :